Paper11700577
A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria.
Shanks GD and 7 others. Clin Infect Dis, 2001. Cited by 130 papers, by iCite.
Cite this record
ConductScience Library. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Papers, record 11700577. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11700577
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminoquinolines | Major topic |
| Antimalarials | Major topic |
| Malaria, Falciparum | Major topic |
| Adolescent | |
| Adult | |
| Animals | |
| Chemoprevention | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Plasmodium falciparum | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05203744 | Escalating Monthly Doses of Tafenoquine in Healthy Volunteers | Background |
Source ClinicalTrials.gov
Cited by66
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 130 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42188870 | Tafenoquine: A Breakthrough Option for Babesiosis Treatment. | Trop Med Infect Dis | 2026 | https://conductscience.org/library/papers/42188870 | PubMed |
| 40305823 | The discovery of chloramphenicol treatment for both scrub typhus and typhoid fever. | MSMR | 2025 | https://conductscience.org/library/papers/40305823 | PubMed |
| 40132008 | Performance of quantitative point-of-care tests to measure G6PD activity: An individual participant data meta-analysis. | PLoS Negl Trop Dis | 2025 | https://conductscience.org/library/papers/40132008 | PubMed |
| 38837364 | The human malaria-Aotus monkey model: a historical perspective in antimalarial chemotherapy research at the Gorgas Memorial Laboratory-Panama. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/38837364 | PubMed |
| 38728310 | The PreQuine Platform: A novel diagnostic tool for measuring glucose-6-phosphate dehydrogenase (G6PD) activity and hemoglobin concentration. | PLoS One | 2024 | https://conductscience.org/library/papers/38728310 | PubMed |
| 38687748 | Field evaluation of a novel semi-quantitative point-of-care diagnostic for G6PD deficiency in Indonesia. | PLoS One | 2024 | https://conductscience.org/library/papers/38687748 | PubMed |
| 38259757 | Vivax malaria: a possible stumbling block for malaria elimination in India. | Front Public Health | 2023 | https://conductscience.org/library/papers/38259757 | PubMed |
| 38241389 | Field assessment of the operating procedures of a semi-quantitative G6PD Biosensor to improve repeatability of routine testing. | PLoS One | 2024 | https://conductscience.org/library/papers/38241389 | PubMed |
| 37242320 | A Review of the Current Status of G6PD Deficiency Testing to Guide Radical Cure Treatment for Vivax Malaria. | Pathogens | 2023 | https://conductscience.org/library/papers/37242320 | PubMed |
| 36472067 | The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis. | Elife | 2022 | https://conductscience.org/library/papers/36472067 | PubMed |
| 35544095 | Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial. | Lancet Microbe | 2022 | https://conductscience.org/library/papers/35544095 | PubMed |
| 34526770 | Safety and Efficacy of Tafenoquine for Plasmodium vivax Malaria Prophylaxis and Radical Cure: Overview and Perspectives. | Ther Clin Risk Manag | 2021 | https://conductscience.org/library/papers/34526770 | PubMed |
| 34495956 | Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria. | PLoS Negl Trop Dis | 2021 | https://conductscience.org/library/papers/34495956 | PubMed |
| 34270547 | Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria. | PLoS Negl Trop Dis | 2021 | https://conductscience.org/library/papers/34270547 | PubMed |
| 34050367 | Single loading-dose tafenoquine for malaria chemoprophylaxis during brief travel? | J Travel Med | 2021 | https://conductscience.org/library/papers/34050367 | PubMed |
| 33979164 | Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1H)-Quinolones with Single Dose Cures. | J Med Chem | 2021 | https://conductscience.org/library/papers/33979164 | PubMed |
| 33306921 | Tafenoquine: a toxicity overview. | Expert Opin Drug Saf | 2021 | https://conductscience.org/library/papers/33306921 | PubMed |
| 32892362 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. | Cochrane Database Syst Rev | 2020 | https://conductscience.org/library/papers/32892362 | PubMed |
| 32169086 | Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review. | Malar J | 2020 | https://conductscience.org/library/papers/32169086 | PubMed |
| 32036613 | Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency. | Med J Aust | 2020 | https://conductscience.org/library/papers/32036613 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11700577
GET https://conductscience.org/api/papers/v1/11700577/cited_by?page=2